A Note About Errata
The publisher, editors, authors, and other contributors have made every effort to ensure the accuracy and completeness of the information presented in the 16th edition of the Handbook of Nonprescription Drugs. From time to time, however, inadvertent errors are found in many books. We will post any substantive errors discovered in the Handbook as soon as possible—after the material in question has been researched thoroughly by the authors.
To report substantive errata, please e-mail your comment with supporting documentation to Webmaster@otchandbook.com.
Scroll down the page to view errata posted to date.
Erratum for Chapter 2, "Patient Assessment and Consultation"
The following correction should be made on page 31, column 1, bullet 3: Kaolin-pectin and attapulgite are not available over the counter. These agents should be removed from the list of nonprescription antidiarrheals.
Kaopectate, a brand-name antidiarrheal product, originally contained kaolin and pectin as its active ingredients. The product was reformulated with attapulgite in 1992 and again in 2003 to contain bismuth subsalicylate. The latter agent has a Pregnancy Category C rating and should not be used when breast-feeding.
Erratum for Chapter 17, "Diarrhea"
Please note the following correction for text on page 301, column 2, paragraph 2, sentence 3: This sentence should be replaced with the following text (corrected text in bold):
BBS has an FDA Pregnancy Category C rating (Briggs GG, Freeman RK, Yaffe JF. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008). It is recommended that products containing this drug be used sparingly or not at all during pregnancy because of concerns that the salicylate component may inhibit platelet function and, in the third trimester, cause premature closure of the fetal ductus arteriosus.27,29
Erratum for Chapter 31, "Prevention of Hygiene-Related Oral Disorders"
Please note the following correction on page 600 to the box "Patient Education for Hygiene-Related Denture Problems," first column, second bullet: "If using an alkaline peroxide or acid cleanser..." should read "If using a hypochlorite or an acid cleanser..."
Erratum for Chapter 32, "Oral Pain and Discomfort"
The following revision has been suggested for Figure 32-4 on page 618: Adding an arrow to box 3 in column 2 that extends to box 7 in column 1.
Erratum for Chapter 43, "Fungal Skin Infections"
Please note the following correction to Figure 43-1 on page 780: In column 1, box 3, “1:400” should read “1:40.”
Errata for Chapter 45, "Minor Foot Disorders"
Please note the following corrections for this chapter:
Table 45-3 on page 806: As indicated in the referenced text, the last bullet in the table should read “Repeat every 48 hours…”
For products containing salicylic acid identified in §358.510(a). “Wash affected area and dry thoroughly.” (If appropriate: “Cut plaster to fit corn/callus.”) “Apply medicated plaster. After 48 hours remove the medicated plaster. Repeat this procedure every 48 hours as needed for up to 14 days (until corn/callus is removed).” (Optional: “May soak corn/callus in warm water for 5 minutes to assist in removal.”)1
Reference
1. Electronic code of Federal Regulations. Corn and callus remover drug products. Fed. Regist. 1990;55:33261. Available at: http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&rgn=div6&view=text&node=21:5.0.1.1.28.6&idno=21. Accessed October 29, 2009.
Page 818, column 1, paragraph 2, last sentence: This sentence should be replaced with the following text:
Sodium sulfide was reclassified as a monograph ingredient for treatment of ingrown toenail on June 6, 2003. After reviewing new data, the Food and Drug Administration concluded that “the data support OTC drug monograph status for 1 percent sodium sulfide in a gel vehicle applied topically for the relief of discomfort (pain) of ingrown toenail. The product is used with a retainer ring to keep the product at the area of application.” 1
Reference
1. Food and Drug Administration. Ingrown toenail relief drug products for over-the-counter human use: final rule. Fed. Regist. 2003;68:24347.